The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases results from the turkbio registry

USLU S., CAN G., ŞENEL S., DALKILIÇ H. E., İNANÇ G. N., AKAR S., ...More

EULAR2018, 13 - 16 June 2018

  • Publication Type: Conference Paper / Summary Text
  • Bursa Uludag University Affiliated: Yes